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Objective: To determine the survival in a population of German 
patients with Duchenne muscular dystrophy.
Patients and methods: Information about 94 patients born be-
tween 1970 and 1980 was obtained by telephone interviews and 
questionnaires. In addition to age of death or actual age during 
the investigation, data concerning clinical course and medical in-
terventions were collected.
Results: 67 patients with molecularly confirmed diagnoses had 
a median survival of 24.0 years. Patients without molecular con-
firmation (clinical diagnosis only) had a chance of 67 % to reach 
that age. Grouping of our patient cohort according to the year of 
death (before and after 2000), ventilation was recognized as main 
intervention affecting survival with ventilated reaching a median 
survival of 27.0 years. For those without ventilation it was 19.0 
years.
Conclusion and clinical relevance: our study provides survival 
data for a cohort of DMD patients in Germany stratified by year 
of death. Median survival was 24.0 years in patients confirmed 
by molecular testing. Ventilated patients had a median survival 
of 27 years. We consider this piece of information helpful in the 
medical care of DMD patients. 
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Introduction
Duchenne muscular dystrophy (DMD) affects 1 in 
3500 male live births  (1), showing the classical pattern 
of X-linked inheritance (2). Out-of-frame mutations dis-
rupt the open reading-frame and lead to severe deficiency 
of the protein dystrophin (2, 3). The reading-frame rule 
was shown to be correct in 93 % of deletion cases and 
66 % of duplication cases (4). Clinical features and an el-
evated serum creatine kinase level (50-100 times normal) 
are important in establishing the diagnosis (5). Molecular 
confirmation reveals 60-65 % deletions, 7 % duplications 
and 21 % point mutations (6, 7). As the underlying muta-
tion is not found in at least 4 % of cases (8), and due to 
a possible discrepancy between mutation and phenotype, 
a muscle biopsy is indicated in patients without a detect-
able mutation (5). Biopsy material is tested via immuno-
histochemistry and Western blot analysis (9, 10). Clinical 
signs, like delay in walking and loss of it, are accompanied 
by progressive muscular weakness. Complete wheelchair 
dependence is usually reached by the age of 12 years (5). 
In more advanced stages, patients are affected by contrac-
tures and progressive scoliosis  (9). There is no curative 
treatment but patients have been shown to benefit from 
glucocorticoid corticosteroids medication, physiotherapy, 
spinal surgery and noninvasive ventilatation (NIV) (11). 
The first sign of incipient respiratory failure is nocturnal 
hypoxia  (9). Mean survival for patients having diurnal 
hypercapnoea amounts to only 9.7 months  (5). NIV is 
the method of choice for treatment of respiratory failure 
and can prolong life (12). Current experimental treatment 
strategies aim at the production of a shorter but functional 
dystrophin protein by exon skipping. Respective clini-
cal trials using antisense oligonucleotides currently have 
reached phases II and III (13).
Patients and methods
Patients: Of our cohort of 94 patients, a data base cov-
ering medical history, medical interventions and survival 
was established. At the time of data collection (summer 
of 2009) 56 patients had already died. Data collection in-
volving patients born between 1970 and 1980 relied on 
the administrative database of the Department of Human 
Genetics, University of Wuerzburg. All patients with a 
proven out-of-frame mutation were included. Addition-
ally, our patient cohort was extended with the help of the 
German family support group (Deutsche Gesellschaft 
für Muskelkranke e. V. (DGM)). Members of the DGM 
were included when “registered as a DMD patient”. Pa-
tients who were not born between 1970 and 1980 were 
excluded. Also excluded were patients living outside of 
Germany. 90 families were contacted from Wuerzburg, 
76 families from the DGM.
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Methods: Patient files of the Department of Human 
Genetics, University of Wuerzburg, were reviewed in or-
der to collect data of birth and contact details, followed 
by telephone interviews with family members of DMD 
patients. They were asked by letter to take part in the sur-
vey. Out of the 87 families who participated in the study, 
11 families preferred to fill in a questionnaire correspond-
ing to the interview questions. Prior to beginning with the 
interview, the telephone partner was asked to provide in-
formed consent. Our study design was approved by the 
local ethics committee.
Statistical analyses: Kaplan-Meier curves were com-
puted to determine median survival (14). Predictive Anal-
ysis SoftWare 18 (PASW 18) was used to compare the 
2 patient groups divided according to way of diagnosis. 
Methods used were the Mann–Whitney–Wilcoxon-test, 
the Fisher’s exact test and the Log rank test (15-17).
Results
A total of 94 patients with DMD formed the study 
cohort that was divided into 2 groups. 67 patients (71 %) 
were in the confirmed molecular diagnosis group, 27 pa-
tients (29 %) were in the clinical diagnosis only group. 
This division was made to ensure that milder types of 
muscular dystrophy would not confound the survival sta-
tistics of the first group.
For the cohort of 67 patients, median age at diagnosis 
was 4.0 years (range 0-10). They achieved independent 
ambulation at a median age of 15.5 months (range 9-48). 
The median age of first wheelchair use was 10.0 years 
(range 6-15) for the 67 boys. Ventilation was introduced 
at a median age of 20.0 years (range 9-30). There was 
a significant correlation between age of getting the first 
wheelchair and age of death (p = 0.016 Pearsons r, 0.383).
The probability of surviving to at least the age of 24 
years was 67 % for patients with clinical diagnosis only. 
Without molecular testing, we cannot rule out milder 
forms like Becker type of muscular dystrophy among this 
patient cohort. The probability of reaching 24 years was 
50 % for subjects with DMD diagnosed on a molecular 
level. This group included 67 patients with a proven out-
of-frame mutation.
Previous reports showed exceptions to the reading-
frame rule concerning deletions  (18-23) and duplica-
tions (24, 25). In these cases of exceptional out-of-frame 
mutations, there is a partly functional dystrophin protein 
that normally occurs in the Becker muscular dystrophy 
(BMD) as a consequence of an in-frame mutation. To 
verify 18 deletions and 10 duplications, former findings of 
muscle biopsy were considered. Due to the lack of infor-
mation about the gene product in the findings, it was not 
possible to make a statement on the course of the disease. 
As there was no statistically significant difference between 
the possible exceptions and the remaining out-of-frame 
mutations, no possible exception mutation was excluded.
Patients diagnosed on the molecular level had a me-
dian survival of 24.0 years (95  % confidence interval 
21.3-26.7 years)  (Fig. 1). It is estimated to be the most 
important result of this study, since up to now such data 
have not been available in Germany. Among medical in-
tervention, ventilation emerged as the most significant 
life-prolonging measure. The median survival of non-
ventilated patients was 19.0 years (95 % confidence in-
terval 17.7-20.3 years) compared to 27.0 years for those 
who were ventilated (95 % confidence interval 20.2-33.8 
Figure 1. Survival curves (Kaplan Meier) for two patient 
cohorts. The green line shows percentage survival for 67 
patients with molecularly proven diagnosis. The blue line 
reflects percentage survival for 27 patients with clinical 
diagnosis only (p = 0.028, log rank test). The black line 
represents the sum of all patients.
Figure 2. Survival curves (Kaplan Meier) for ventilated 
versus non-ventilated patients diagnosed at the molecular 
level. The green line denotes percentage survival for 44 
ventilated patients. Information about details of ventilation 
is not available. The blue line shows percentage survival 
for 22 non-ventilated patients (p < 0.001, log rank test).
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Jahre). As shown in Figure 2, there was a statistically sig-
nificant difference between the respective survival curves 
(Log rank p < 0,001).
Discussion
Our study population consisted of patients with dif-
ferent diagnosis criteria. The majority of patients with an 
identified mutation were registered with the Department 
of Human Genetics, University of Wuerzburg, serving 
as reference center for DMD until 1985. Additional 10 
patients with confirmed molecular diagnosis were re-
cruited via the family support group DGM. Other DGM 
patients lacked molecular confirmation and were there-
fore included as a separate group. There was no statis-
tically significant difference between the groups but for 
theoretical reasons the division was maintained. As illus-
trated in Figure 1, a tendency for a survival benefit sug-
gests the putative presence of milder types of muscular 
dystrophy within the group “clinical diagnosis only”. It 
is conceivable that this effect was caused by some boys 
having BMD, since the median survival of BMD patients 
amounts to 42 years (26).
Age at and cause of death are important clinical pa-
rameters. In 13 of our 45 deceased patients the cause of 
death was unknown. In literature, major reported causes 
of death are heart failure and respiratory insufficiency (5). 
Due to interviews with medical laymen, cardiac aspects 
like cardiomyopathy have not been considered. We un-
derstood every cause of death to be associated with the 
disease DMD and included patients no matter what cause 
of death they died of.
Reports from Newcastle  (27,  28) and a prospective 
study of 43 patients with DMD by Kohler et al. (29) de-
termined survival in terms of years of life, facilitating a 
comparison with the present study. Eagle et al.  (27) di-
vided their subjects into groups according to the decade 
in which they died. A later study by the same authors fo-
cused on the life-prolonging effects of ventilation and spi-
nal surgery (28). Our data were not sufficient for survival 
analyses of a separate surgery group, since only 12 of 
our cohort of molecularly confirmed 67 patients had un-
dergone spinal surgery. We therefore compared the 2002 
study by Eagle et al. (27) to the present report. Dividing 
our patients up into groups “died before 2000” and “died 
after 2000”, a difference in survival due to use of ventila-
tion emerged (Fisher’s exact test p < 0,001). As reported 
by a number of other authors, our study confirms that ven-
tilation improves life expectancy. For example, Yasuma 
et al.  (30) reported a median survival for non-ventilated 
patients of 20.1 years and Eagle et al. (27) reported 19.3 
years. In contrast, median survival of patients using ven-
tilation amounted to 30.4 years (30) and 25.3 years (27).
Since our study did not intent to evaluate therapies, 
mode of ventilation and indication to ventilation were 
not separately studied. We only recorded median age at 
introduction of ventilation. Studies considering proto-
cols for ventilation showed the impact of home nocturnal 
ventilation on longevity. Recent studies on NIV revealed 
an improved median survival of 31 and 35 years respec-
tively (31, 29). Compared to our study, factors like study 
design and other interventions influencing survival (e. g. 
spinal surgery, treatment of heart conditions) could ex-
plain this impressive survival advantage. However, our 
observed difference between non-ventilated and venti-
lated patients (19.0 vs. 27.0 years) clearly supports the 
important impact ventilation has on survival.
Conclusion
Duchenne muscular dystrophy is still not curable but 
can be treated to improve the quality of life and survival. 
Our study suggests that ventilation therapy has the most 
important impact on survival which is in agreement with 
recent international studies with long-term ventilated 
DMD patients. Clearly, a central feature of the manage-
ment of Duchenne muscular dystrophy should be ventila-
tion therapy. Other than confirming the beneficial effects 
of ventilation, the most important result of our retrospec-
tive study is a median survival of 24.0 years for a cohort 
of molecularly confirmed DMD patients. Up to now such 
data were not available for German patients. The results 
of our study might therefore be useful for genetic coun-
seling and for families with affected boys in general.
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